Tuberculosis

Print

altThe Tuberculosis Programme Area Component contributes to the reduction of the Tuberculosis (TB) disease burden in the WHO Africa Region through support to all member states to adopt and implement cost-effective TB prevention, treatment, care and support interventions.


Improved data reveals higher global burden of tuberculosis

22 October 2014 -- Recent intensive efforts to improve collection and reporting of data are shedding new light on the epidemic, revealing almost half a million more cases than previously estimated. WHO’s “Global Tuberculosis Report 2014” shows that 9 million people developed TB in 2013, and 1.5 million died, including 360 000 people who were HIV positive. However, the mortality rate from TB is still falling and the number of people developing the disease is declining by an average 1.5% a year.


What is multidrug-resistant tuberculosis and how do we control it?

Online Q&A

Q: What is multidrug-resistant tuberculosis and how do we control it?

A: The bacteria that cause tuberculosis (TB) can develop resistance to the antimicrobial drugs used to cure the disease. Multidrug-resistant tuberculosis (MDR-TB) is TB that does not respond to at least isoniazid and rifampicin, the two most powerful anti-TB drugs.